Insite Vision Q4 and Year-End 2013 Financial Results Conference Call Today's Calls 
Visit the TF Network Sites
Visit the TF Network Sites
· Corporate IR Center
· Institutional Investor Center
· Individual Investor Center
Download Plug-In
Real Player 8 Basic
Windows Media Player
Other Conference Calls
Other Mar 27 Calls
Today's Calls
Call Details
Insite Vision Q4 and Year-End 2013 Financial Results Conference Call
Scheduled to start Thu, Mar 27, 2014, 4:30 pm Eastern

-- this event is ongoing now--
Listen to the ongoing live event audio stream

About InSite Vision Inc (Other OTC:INSV)
InSite Vision Incorporated develops novel ophthalmic products designed for unmet eye care needs. It is developing ophthalmologic products for unmet eye care needs based on its DuraSite platform technologies. The company’s lead product is AzaSite, a macrolide antibiotic for the treatment of bacterial conjunctivitis caused by susceptible isolates of various microorganisms. It also markets Besivance, a besifloxacin ophthalmic suspension to treat bacterial conjunctivitis. In addition, InSite Vision is preparing a new drug application for the commercial approval of BromSite by the U.S. Food & Drug Administration for the prevention of pain and inflammation associated with ocular surgery; and advancing two novel ophthalmic therapeutics through Phase 3 clinical studies comprising AzaSite Plus and DexaSite for the treatment of eye infections. Further, it has a pipeline of earlier-stage product candidates based on its platform technologies. The company has commercial partnerships with Merck & Co., Bausch & Lomb, and Pfizer Inc. The company was founded in 1986 and is based in Alameda, California.


More Info: Quote | Profile | Reports | Research | Insider | Financials | Analyst Ratings


Copyright © 2014 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Copyright © 2014 FirstCall Events. Historical chart data provided by Commodity Systems, Inc. (CSI). Company profile information presented on this page is Copyright Capital IQ. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.